Open-Label Study of AG10 in Patients with Cardiomyopathy

Summary

This prospective, multicenter open-label study will evaluate the long-term safety, tolerability, PK and PD of AG10 administered on a background of stable heart failure therapy.

Timeline

Start

2018-08-08

Primary completion

2027-07

Completion

2027-07

Outcome

Met primary endpoint

release “The study met its primary objective of establishing that AG10 was well tolerated with no safety signals of potential clinical concern” bridgebio.com ↗

Publications

• Testani JM, Judge DP, Borlaug BA, Cherney D, Cox ZL, Gillmore JD, Lewis JB, Adler SH, Cao X, Castano A, Fox JC, Katz L, Mathur V, Xiong K, Butler J, Masri A. Effects of Acoramidis on Kidney Function in Transthyretin Amyloid Cardiomyopathy. Circ Heart Fail. 2026 Jul 2:e014656. doi: 10.1161/CIRCHEARTFAILURE.126.014656. Online ahead of print.

Drugs

Indications